HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
Terazosin
TERAZOSIN HCL · terazosine · Urodie · HYTRIN · erazosin · arbonyl)- · Terazosin · CID 663211
Identifikatoren & physikalische Daten
| CAS No. | 63590-64-7 |
|---|---|
| Summenformel | C19H25N5O4 |
| Durchschnittliche Molmasse | 387,4 g/mol |
| Monoisotopische Masse | 387,19065428 g/mol |
| SMILES | COc1cc2nc(N3CCN(C(=O)C4CCCO4)CC3)nc(N)c2cc1OC |
| InChIKey | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| PubChem CID | 5401 |
| ChEMBL | CHEMBL611 |
| ChEBI | CHEBI:9445 |
| EC No. | 613-265-8 |
| DTXSID | DTXSID3023639 |
Chemische & physikalische Eigenschaften
| XLogP | 1,4 |
|---|---|
| Polarare Oberfläche (TPSA) | 103 |
| H-Brücken-Donoren | 1 |
| H-Brücken-Akzeptoren | 8 |
| Frei drehbare Bindungen | 4 |
| Schwere Atome | 28 |
| Formalladung | 0 |
| Komplexität | 544 |
| Arzneimittel | Pharmaceuticals -> Antihypertensives |
| LogP (Verteilungskoeffizient) | 11.14 |
| Löslichkeit | 1.50e+00 g/LH2O: 25 mg/mL30.6mg/L(22.5 ºC) |
| Human Drugs | Breast FeedingLactationMilk, HumanAdrenergic alpha-AntagonistsAntihypertensive AgentsPharmaceuticals |
| Schmelzpunkt | 271-274273 °C281-283°C |
| Physical Description | Solid |
| Collision Cross Section | 189.79 Ų [M+Na]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| Siedepunkt | 664.5±65.0 °C(Predicted) |
| Dichte | 1.332±0.06 g/cm3(Predicted) |
| Lagerbedingungen | -20°C Freezer |
| Aggregatzustand | powder |
| pKa (Säurekonstante) | pKa (0.1N NaOH): 7.1(at 25℃) |
| Farbe | white to off-white |
| BCS Class | 1/3 |
| InChIKey | VCKUSRYTPJJLNI-UHFFFAOYSA-N |
| CAS Datenbank | 63590-64-7(CAS DataBase Reference) |
Sicherheit & Vorschriften
| GHS-Einstufung | This chemical does not meet GHS hazard criteria for 2.3% (1 of 44) of reports.WarningH302 (97.7%): Harmful if swallowed [Warning Acute toxicity, oral]P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 44 reports by companies from 3 notifications to the ECHA C&L Inventory. |
|---|---|
| Regulatorische Informationen | Status: Active Update: 25-07-2018 https://echa.europa.eu/registration-dossier/-/registered-dossier/25502 |
| Hazard Classes and Categories | Acute Tox. 4 (97.7%) |
| Treatment | Should overdosage of Terazosin lead to hypotension, support of the cardiovascular system is of first importance. Restoration of blood pressure and normalization of heart rate may be accomplished by keeping the patient in the supine position. If this measure is inadequate, shock should first be treated with volume expanders. If necessary, vasopressors should then be used and renal function should be monitored and supported as needed. Laboratory data indicate that Terazosin is highly protein boundtherefore, dialysis may not be of benefit. (L1712) |
| Gesundheitliche Auswirkungen | Hypotension, palpitations, postural hypotension, syncope, peripheral edema, weight gain, dyspnea, nasal congestion/rhinitis, impotence. |
| Hepatotoxicity | Terazosin has been associated with a low rate of serum aminotransferase elevations that in controlled trials was no higher than with placebo therapy. These elevations were transient and did not require dose modification. Instances of serum enzyme elevations, but no instances of clinically apparent acute liver injury with jaundice due to terazosin, have been published. Furthermore, product labels do not include discussion of hepatic toxicity. Cholestatic hepatitis and jaundice have been reported with other alpha-adrenergic blockers. Thus, acute symptomatic liver injury due to terazosin must be exceedingly rare if it occurs at all. |
| Unerwünschte Wirkungen | Terazosin is generally well-tolerated. Many adverse effects of terazosin are explainable due to its blockade of alpha-1 adrenergic receptors. |
| Expositionspfade | Oral. Essentially completely absorbed in man (90% bioavailability). |
| Toxizitätsübersicht | Overdose of terazosin may lead to hypotension, and standard life-support protocols should be in place for instances of hemodynamic instability. There are no specific antidotes for terazosin toxicity. Vasopressors may be used to support physiologic blood pressure parameters in the event of terazosin overdose. Terazosin is long-acting, with an elimination half-life of approximately 12 hours, and is highly protein-bound. Elimination is via renal excretion (40%) and excretion of feces (60%).Terazosin selectively and competitively inhibits vascular postsynaptic alpha(1)-adrenergic receptors, resulting in peripheral vasodilation and a reduction of vascular resistance and blood pressure. Unlike the nonselective alph-adrenergic blockers phenoxybenzamine and phentolamine, terazosin does not block presynaptic alpha(2)-receptors and, hence, does not cause reflex activation of norepinephrine release to produce reflex tachycardia. |
| Signs and Symptoms | Asthenia, postural hypotension, dizziness, somnolence, nasal congestion/rhinitis. |
| Carcinogen Classification | No indication of carcinogenicity to humans (not listed by IARC). |
| Drug Induced Liver Injury | Drug-Induced Liver Injury Severity and Toxicity (DILIst)terazosinDILI NegativeOralDOI:10.1016/j.drudis.2019.09.022 |
| Effects During Pregnancy and Lactation | ◉ Summary of Use during Lactation |
| Toxicity Data | LD50: 259.3mg/kg (parental-intravenous, Mouse) (A308) |
| Wassergefährdungsklasse (WGK) | 3 |
| RTECS-Nr. | TK8044925 |
| R-Sätze (R) | 22-36/37/38 |
| Gefahrensymbole | Xn,Xi |
| Sicherheitshinweise (S) | 26-36 |
Anwendungen & Verwendung
Verwenden
Terazosin is used for the same indications as is prazosin; however, it has the advantage of being able to be used once a day.